Polyphor is a development-stage company focused on oncology and antibiotics. Its lead programme is balixafortide, a CXCR4 inhibitor currently in Phase III for breast cancer. Data are expected in 2021. The company plans to start its Phase I programme of inhaled murepavadin to treat P. aeruginosa infections in cystic fibrosis patients by the year end.
In this interview, CEO Gokhan Batur provides an overview of the company’s programmes, especially balixafortide and inhaled murepavadin. He also reviews the Phase Ib data for balixafortide, as well as the design and timelines for the Phase III data expected next year.